Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient

Journal of Trauma - Injury, Infection and Critical Care

Volumn 60, Issue 3, 2006, Pages 648-652

  Trop, Marija ^a,c   Novak, Michael ^a   Rodl, Siegfried ^a   Hellbom, Bengt ^a   Kroell, Wolfgang ^a   Goessler, Walter ^b  

^a Institute of Chemistry   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

Author keywords

Acticoat; Burns; Silver toxicity

Indexed keywords

ACTICOAT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LIVER ENZYME; PARACETAMOL; POLYESTER; POLYETHYLENE; SILVER; SULFADIAZINE SILVER; UREA; TOPICAL ANTIINFECTIVE AGENT;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARGYRIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BLOOD LEVEL; BURN; BURN DRESSING; CASE REPORT; DRUG WITHDRAWAL; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MALE; NANOCRYSTAL; PRIORITY JOURNAL; PSEUDOMONAS; URINE LEVEL; WOUND DRESSING; BANDAGE; BLOOD; DIFFERENTIAL DIAGNOSIS; LIVER FUNCTION TEST; TOXIC HEPATITIS;

ADOLESCENT; ALANINE TRANSAMINASE; ANTI-INFECTIVE AGENTS, LOCAL; ARGYRIA; ASPARTATE AMINOTRANSFERASES; BANDAGES; BURNS; DIAGNOSIS, DIFFERENTIAL; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE; SILVER; SILVER SULFADIAZINE;

EID: 33645550402     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000208126.22089.b6     Document Type: Article

References (27)

1. Barret JP, Herndon DN. Effects of burn wound excision on bacterial colonisation and invasion. Plast Recon Surg. 2003;111:744-750.
2. Sheridan R. The seriously burned child: resuscitation through reintegration. Cuff Probl Pediatr. 1998:105-126.
3. Wright JB, Lam K, Burret AG, Olson ME, Burrell RE. Early healing events in a porcine model of contaminated wounds: effects of nanocristalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen. 2002;10:141-151.
4. Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev. 2003;27:341-353.
5. Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns. 2000;26:131-138.
6. Sano S, Fujimori R, Takashima M, Itokawa Y. Absorption, excretion and tissue distribution of silver sulfadiazine. Burns Incl Therm Inj. 1981;8:278-285.
7. Wang XW, Wang NZ, Zhang OZ, Zapata-Sirvent RL, Davies JW. Tissue deposition of silver following topical use of silver sulphadiazine in extensive burns. Burns Incl Therm Inj. 1985; 11:187-201.
8. Maitre S, Jaber K, Perrot JL, Guy C, Cambazard F. Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine (Flammazine). Ann Dermatol Venereol. 2002;129:217-219.
9. Bossalis MG, McCall JT, Ahrenholz DH, Solem LD, McClain CJ. Serum and urinary silver levels in thermal injury patients. Surgery. 1987;101:40-43.
10. Coombs CJ, Wan AT, Masterton JP, et al. Do burn patients have a silver lining? Burns. 1992;18:179-184.
11. McKenna SR, Latenser BA, Jones LM, et al. Serious silver sulpadiazine and mafenide acetate dermatitis. Burns. 1995;21:310-312.
12. Lockhart SP, Rushworth A, Azmy AA, Raine PA. Topical silver sulphadiazine: side effects and urinary excretion. Burns Incl Therm Inj. 1983;10:9-12.
13. Iwasaki S, Yoshimura A, Ideura T, Koshikawa S, Sudo M. Elimination study of silver in a hemodialyzed burn patient treated with silver sulfadiazine cream. Am J Kidney Dis. 1997;30:287-290.
14. Caffee HH, Bingham HG. Leukopenia and silver sulfadiazine. J Trauma. 1982;22:586-587.
15. Fuller FW, Engler FE. Leukopenia in non-septic patients receiving topical 1% silver sulfadiazine cream therapy: a survey. J Burn Care Rehabil. 1988;9:606-609.
16. Thomson PD, Moore NP, Rice TL, Prasad JK. Leukopenia in acute thermal injury: evidence against topical silver sulfadiazine as the causative agent. J Burn Care Rehabil. 1989;10:418-420.
17. Kiker RG, Carvajal HF, Milcak RP, Larson DL. A controlled study ofthe effects of silver sulfadiazine on white blood cell counts in burned children. J Trauma. 1977;17:835-836.
18. Gamelli RL, Paxton TP, O'Reilly M. Bone marrow toxicity by silver sulfadiazine. Surg Gynecol Obstet. 1993;177:115-120.
19. Burrell RE. The in vitro and in vivo antimicrobial potency of a new silver coated dressing for wound care. 51OK K955453; Washington DC: 1997.
20. Tredget EE, Shankowsky HA, Groeneveld A, Burrell R. A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil. 1998;19:531-537.
21. Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of Acticoat antimicrobial barrier dressing. J Burn Care Rehabil. 1999;20:195-200.
22. Innes ME, Umraw N, Fish IS, Gomez M, Cartotto RC. The use of silver coated dressing on donor site wounds: a prospective, controlled matched pair study. Burns. 2001;27:621-627.
23. Demling RH, DeSanti. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns. 2002;28:264-266.
24. Holder IA, Durkee P, Stipp AP, Boyce ST. Assessment of silver-coated barrier dressing for potential use with skin grafts on excised burns. Burns. 2003;29:445-448.
25. Thomas S, McCubbin P. A comparison of the antimicrobial effects of four silver containing dressings on three organisms. J Wound Care. 2003;12:101-107.
26. Rowland-Payne CMR Bladin C, Colchester ACF, et al. Argyria from excessive use of topical silver sulphadiazine. Lancet. 1992;340:126.
27. Wan AT, Conyers RA, Coombs CI, Masterton JP. Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem. 1991;37:1683-1687.